Navigation Links
Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
Date:12/11/2013

ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014.

The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately 500,000 shares of Questcor common stock through December 10, 2013. The shares were purchased at an average price of $57.21 per share.

Through its repurchase program and its dividend, Questcor has returned approximately $440 million to shareholders since the beginning of 2008, representing approximately 60% of its operating cash flow over that same period.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following approved indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
2. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
3. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
4. Questcor Honored as an "Everyday Hero" by NephCure Foundation
5. Questcor Adds G. Kelly Martin to Board of Directors
6. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
7. Questcor Reports Third Quarter Financial Results
8. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
11. Questcor to Commence Phase 2 Study of Acthar for ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017 Provides understanding and access to ... into by the worlds leading healthcare companies. ... Description The Global Renal Failure Partnering Terms and ... to partnering deals and agreements entered into by ... Trends in partnering deals - Top deals ...
(Date:2/20/2017)... 20, 2017 The report analyzes the worldwide markets for Drug-Eluting ... the US, Canada , Japan ... Latin America , and Rest of World. ... ... provided for the period 2015 through 2022. Also, a six-year historic ...
(Date:2/20/2017)... Feb. 20, 2017 This report analyzes the worldwide ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , and Rest ... http://www.reportlinker.com/p04707131-summary/view-report.html Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... 2017 , ... "At your fingertips" electronic access to patient ... Delaware Health Information Network (DHIN) have partnered to improve connectivity of this data ... exchange, DHIN stores and shares real-time health data for more than 2 million ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, ... in the industry, according to the recent NEJM Catalyst Insights Report on the ... the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network ... prescribing of controlled and non-controlled substances plus the ability to manage orders on ... United States now accept electronic prescriptions, according to the Office of the National ...
Breaking Medicine News(10 mins):